Study S000010

A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03131687
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 318
Start: 2017-05-24
Primary completion: 2018-08-01
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:tirzepatide; DRUG:Dulaglutide; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-MC-GPGB; EUDRACT_NUMBER:2016-004179-33; NIH:2016

Registered primary outcomes

Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c) Bayesian Dose Response [Baseline, Week 26]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007808	Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. Pirro V, The Journal of clinical endocrinology and metabolism	2022	Randomized trial	PMID 34608929 DOI	cites ClinicalTrials.gov:NCT03131687; registry reference DERIVED:34608929
R0012252	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Sattar N, Nature medicine	2022	Systematic review	PMID 35210595 DOI	cites ClinicalTrials.gov:NCT03131687; registry reference DERIVED:35210595
R0015733	Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Hartman ML, Diabetes care	2020	Other trial	PMID 32291277 DOI	cites ClinicalTrials.gov:NCT03131687; registry reference DERIVED:32291277
R0016215	Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Frias JP, Lancet (London, England)	2018	Randomized trial	PMID 30293770 DOI	cites ClinicalTrials.gov:NCT03131687; registry reference DERIVED:30293770